University of Southern California
Oncology
Dr. David B. Agus, MD
|
|
Give Review
David Agus is an expert in the field of Oncology. He went to Perelman School of Medicine at the University of Pennsylvania. He received awards:"Regional Top Doctor", "Super Doctor" and "Whos Who in Medicine and Healthcare". David B. Agus is a published doctor. He published 72 publications, including: 'Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androge...' He is registered with Medicare and accepts Medicare payments.
Publications
- Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castratio...
- Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate Cancer.
- Intolerance of uncertainty, cognitive complaints, and Cancer-related distress in prostate Cancer survivors.
- Phase I/II Trial of Orteronel (TAK-700)--an Investigational 17,20-Lyase Inhibitor--in Patients with Metastatic Castration-Resistant Prostate Cancer.
- A physical sciences network characterization of non-tumorigenic and metastatic cells.
- A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid Tumors.
- Body image predicts quality of life in men with prostate Cancer.
- Anterior gradient 2 (AGR2): Blood-based biomarker elevated in metastatic prostate Cancer associated with the neuroendocrine phenotype.
- Perspective: Meeting of minds.
- Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
- Safety and pharmacokinetics of high-dose gefitinib in patients with solid Tumors: results of a phase I study.
- Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma.
- Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate Tumors.
- Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate Cancer.
- Beta-2-microglobulin expression correlates with high-grade prostate Cancer and specific defects in androgen signaling.
- Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs.
- HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation.
- Pharmacologic inhibition of Pim kinases alters prostate Cancer cell growth and resensitizes chemoresistant cells to taxanes.
- Multiparameter computational modeling of tumor invasion.
- Precursor-ion mass re-estimation improves peptide identification on hybrid instruments.
- The current state of preclinical prostate Cancer animal models.
- Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate Cancer a...
- Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery.
- 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
- Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
- Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced Cancer.
- CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent Prostate tumor xenografts.
- PPARgamma signaling: one size fits all?
- Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma.
- Ductal adenocarcinoma of the Prostate.
- Targeting the HER-kinase axis in Cancer.
- Update on HER-kinase-directed therapy in prostate Cancer.
- Survival analysis of genome-wide gene expression profiles of prostate Cancers identifies new prognostic targets of disease relapse.
- Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate Cancer.
- Targeting ligand-activated ErbB2 signaling inhibits Breast and prostate tumor growth.
- Vaccination with CD20 peptides induces a biologically active, specific immune response in mice.
- 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate Cancer xenografts.
- CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.
- Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
- A potential role for activated HER-2 in prostate Cancer.
- HER-2/neu as a therapeutic target in non-small cell lung Cancer, prostate Cancer, and ovarian Cancer.
- Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate Cancer xenograft model CWR22-R1.
- Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate Cancer cells in vitro and in vivo.
- Ligand responsiveness in human prostate Cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors.
- Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients wit...
- Prostate Cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence.
- Response of prostate Cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
- Stromal cell oxidation: a mechanism by which Tumors obtain vitamin C.
- Positron emission tomography of a human prostate Cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androge...
- Workgroup 2: human xenograft models of prostate Cancer.
- Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters.
- A human homeobox gene, HB24, inhibits development of CD4+ T cells and impairs thymic involution in transgenic mice.
- Profound atrophy of the bone marrow reflecting major histocompatibility complex class II-restricted destruction of stem cells by CD4+ cells.
- Inhibitory role of dietary protein restriction on the development and expression of immune-mediated antitubular basement membrane-induced tubulointerstitial nephritis ...
- The effects of daily cyclophosphamide administration on the development and extent of primary experimental interstitial nephritis in rats.
- Reentry of T cells to the adult thymus is restricted to activated T cells.
- Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated Prostate tumor growth inhibition.
- Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising Prostate-specific antigen: recommendations from the Prostate-Sp...
- Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke.
- HER-2/neu (p185neu) protein expression in the natural or treated history of prostate Cancer.
- Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies.
- Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate Cancer, NCI-6735. A study by the DOD/PCF prostate ...
- Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate Cancer.
- Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate Cancer.
- ProteoWizard: open source software for rapid proteomics tools development.
- Personalized genetics: a responsible approach.
- A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate Cancer.
- Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate Cancer growth: results from preclinical studies and a pilot phase II cl...
- Predictors of affect following treatment decision-making for prostate Cancer: conversations, cognitive processing, and coping.
- A perspective on protein profiling of blood.
- TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate Cancer cells.
Schools
Perelman School of Medicine University of Pennsylvania
Johns Hopkins Hospital
Meml Sloan Kettering Cancer Center
Conditions Treated
- Anemia
- Breast Cancer
- Coagulation Disorders (incl. Hemophilia)
- Lung Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select PPO
- Access Plus Savenet
- Basic Exclusive PPO for Small Business
- Basic PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Covered California - Bronze PPO
- Health Net PPO
- Individual and Family PPO
- Medicare Advantage PFFS
- Humana
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Regional Top Doctor
- Super Doctor
- Whos Who in Medicine and Healthcare
Education
-
Memorial Sloan-Kettering Cancer Center -
Johns Hopkins University -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
Cedars-Sinai Medical Center -
Keck Hospital of USC
Drug Facts
| NPI NUMBER | 1356328249 | |
| NPPES Provider LastName | AGUS | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 902111837 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 259.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1356328249 |
| Last Name Of The Provider | AGUS |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Patricia S. Gordon, MD |
|
|
Dr. Barry E. Rosenbloom, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philomena F. McAndrew, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dorothy J. Park, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Noam Z. Drazin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nader Javadi, MD
This Doctor is OpenDoctor Recommended.
|